JCP

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
[Advanced]

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Göhring, U-J
Right arrow Articles by Schöndorf, T
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Göhring, U-J
Right arrow Articles by Schöndorf, T
J Clin Pathol 2001; 54:866-870
© 2001 Journal of Clinical Pathology

p21waf correlates with DNA replication but not with prognosis in invasive breast cancer

U-J Göhring, A Bersch, M Becker, W Neuhaus, T Schöndorf

Department of Gynecology and Obstetrics, University of Cologne, 50924 Cologne, Germany

Dr Schöndorf thomas.schoendorf{at}medizin.uni-koeln.de Background/Aims—p21waf plays a central role both in the regulation of the cell cycle and in DNA replication. Accordingly, p21waf is a putative tumour suppressor. The role of p21waf expression in breast cancer is still unclear, particularly with respect to the clinical situation. Therefore, this retrospective study was designed to investigate the value of immunohistochemically detected p21waf expression in invasive breast cancer.

Methods—Cellular expression of p21waf was assessed in 307 breast cancer tissues by immunohistochemistry using the monoclonal antibody, clone 4D10. The data were correlated to established and functional factors of prognosis (age, menopausal status, tumour size, nodal status, tumour grade, receptor status, proliferating cell nuclear antigen (PCNA) expression, Her-2/neu expression, and p53 expression), and to clinical follow up (median observation time, 82 months).

Results—Ninety nine of 307 (32.2%) tumour tissues were considered p21waf positive (nuclear staining). In the entire study group, p21waf expression correlated only with increased PCNA expression ({chi}2 test: p = 0.029), and with none of the other investigated markers. In node negative patients (n = 134), p21waf expression correlated with increased tumour size and increased PCNA expression, whereas the node positive subgroup (n = 161) showed no correlation with these parameters (lymphonodectomy was done in 295 women). With respect to clinical outcome, p21waf expression showed a definite favourable trend in both subgroups (N0: p21waf negative, 23 of 87; p21waf positive, nine of 43. N+: p21waf negative, 63 of 107; p21waf positive, 23 of 52), but this observation was not significant (p > 0.05). Multivariate analysis for disease free survival as indicated by Cox regression analysis included all factors investigated. The most striking parameters were nodal status (relative risk (RR), 1.74; p = 0.00001), receptor status (RR, 0.59; p = 0.0085), tumour size (RR, 1.42; p = 0.02), and Her2/neu expression (RR, 1.56; p = 0.033). p21waf expression was not significant in the multivariate analysis (p > 0.05).

Conclusions—p21waf expression is an independent factor but fails to be of prognostic or predictive value in multivariate analysis. These data confirm the hypothesis of a p53 independent p21waf induction and suggest a functional role in the inhibition of PCNA mediated DNA replication.

Key Words: p21waf • proliferating cell nuclear antigen • p53 • breast cancer • immunohistochemistry • prognosis




This article has been cited by other articles:


Home page
INT J SURG PATHOLHome page
S. Etemad-Moghadam, F. Baghaee, F. Tirgary, P. Motahhary, M. Khalili, N. Eshghyar, M. Alaedini, and M. Eslami
Expression of p21WAF in Salivary Gland Mucoepidermoid Carcinoma and Its Relation to Histologic Grade
International Journal of Surgical Pathology, January 1, 2007; 15(1): 6 - 13.
[Abstract] [PDF]


Home page
Ann OncolHome page
M. Colozza, E. Azambuja, F. Cardoso, C. Sotiriou, D. Larsimont, and M. J. Piccart
Proliferative markers as prognostic and predictive tools in early breast cancer: where are we now?
Ann. Onc., November 1, 2005; 16(11): 1723 - 1739.
[Abstract] [Full Text] [PDF]


Home page
Endocr Relat CancerHome page
A. J Butt, C. M McNeil, E. A Musgrove, and R. L Sutherland
Downstream targets of growth factor and oestrogen signalling and endocrine resistance: the potential roles of c-Myc, cyclin D1 and cyclin E
Endocr. Relat. Cancer, July 1, 2005; 12(Supplement_1): S47 - S59.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
W. Xia, J.-S. Chen, X. Zhou, P.-R. Sun, D.-F. Lee, Y. Liao, B. P. Zhou, and M.-C. Hung
Phosphorylation/Cytoplasmic Localization of p21Cip1/WAF1 Is Associated with HER2/neu Overexpression and Provides a Novel Combination Predictor for Poor Prognosis in Breast Cancer Patients
Clin. Cancer Res., June 1, 2004; 10(11): 3815 - 3824.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Pathol.Home page
M J Pellikainen, T T Pekola, K M Ropponen, V V Kataja, J K Kellokoski, M J Eskelinen, and V-M Kosma
p21WAF1 expression in invasive breast cancer and its association with p53, AP-2, cell proliferation, and prognosis
J. Clin. Pathol., March 1, 2003; 56(3): 214 - 220.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
I. Osman, E. Sherman, B. Singh, E. Venkatraman, M. Zelefsky, G. Bosl, H. Scher, J. Shah, A. Shaha, D. Kraus, et al.
Alteration of p53 Pathway in Squamous Cell Carcinoma of the Head and Neck: Impact on Treatment Outcome in Patients Treated With Larynx Preservation Intent
J. Clin. Oncol., July 1, 2002; 20(13): 2980 - 2987.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
Journal of Clinical Pathology Molecular Pathology
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2001 by the BMJ Publishing Group Ltd & Association of Clinical Pathologists.